EQ Earnings Date: Nov 12, 2026 (Estimated) — Equillium, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is EQ's next earnings date?
Equillium, Inc. (EQ) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05.
How did EQ do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Equillium, Inc. posted EPS of -$0.04 versus the -$0.05 estimate, a beat of 33.3%. Revenue was $0. The stock's 1-day post-earnings move was +17.4%.
How much does EQ stock move after earnings?
EQ beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 16.6% (up or down) in the day after earnings.
About Equillium, Inc.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.05 | -0.04 | +33.33% | $0 | ✅ Beat | +17.41% | +12.94% | +4.23% |
| 2026-05-13 | Q1 2026 | -0.04 | -0.06 | -50.00% | $0 | ❌ Miss | +12.12% | -10.82% | +21.64% |
| 2026-03-25 | Q4 2025 | -0.07 | -0.04 | +42.86% | $0 | ✅ Beat | +0.00% | -0.97% | +4.85% |
| 2025-11-13 | Q3 2025 | -0.19 | -0.06 | +68.42% | $0 | ✅ Beat | +23.81% | +20.24% | +45.24% |
| 2025-08-14 | Q2 2025 | -0.17 | -0.16 | +5.88% | $0 | ✅ Beat | +16.31% | +59.17% | +74.47% |
| 2025-03-27 | Q4 2024 | -0.26 | -0.16 | +38.46% | $4.4M | ✅ Beat | -35.62% | -35.22% | -42.19% |
| 2024-11-13 | Q3 2024 | -0.26 | 0.00 | +100.00% | $12.2M | ✅ Beat | -12.33% | -7.98% | -9.67% |
| 2024-03-25 | Q4 2023 | -0.17 | -0.07 | +58.82% | $9.2M | ✅ Beat | -15.57% | -10.66% | -26.64% |
Showing last 8 quarters.